Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » DiagnoCure

DiagnoCure

Apr 15, 2016

DiagnoCure Board Votes to Liquidate, Dissolve Company

The plan, which is subject to shareholder approval, comes after the company failed to find buyers for its prostate and colorectal cancer tests.

Jan 22, 2016

DiagnoCure's Q4 Revenues Fall as Net Loss Widens

The life sciences company said the loss is mostly attributable to a decrease in royalty revenue from its PCA3 prostate cancer biomarker assets.

Dec 24, 2015

DiagnoCure Sells PCA3 Prostate Cancer Assets to Hologic's Gen-Probe for C$6.5 Million

Hologic will purchase the assets via its subsidiary Gen-Probe, from which DiagnoCure will repurchase Series A shares worth C$1 million.

Mar 06, 2015

DiagnoCure Q1 Revenues Dip 3 Percent

The firm also said that it is looking for marketing partners for its multimarker urine-based prostate cancer test, which was validated in 500 patients.

Jun 06, 2014

In Brief This Week: Agilent Technologies; Diagnocure; KineMed, Pfizer; PositiveID; SomaLogic

NEW YORK (GenomeWeb) – Agilent Technologies said this week that it has mad an adjustment to its second quarter 2014 GAAP net income.

Jun 05, 2014

DiagnoCure Licenses Multi-Marker CRC Staging Test to China's Shuwen Biotech

Premium

NEW YORK (GenomeWeb) — Canadian cancer diagnostics firm DiagnoCure said this week that it has granted an exclusive license to China's Shuwen Biotech to commercialize DiagnoCure's Previstage GCC colorectal cancer staging test in China, Hong Kong, and Taiwan.

Mar 20, 2014

DiagnoCure Prods Commercial Partner Hologic to Step Up Marketing for PCA3 Test or Give it Back

Premium

Unhappy with the sales of its urine-based molecular test for the prostate cancer biomarker PCA3, Canadian cancer diagnostics firm DiagnoCure is urging Hologic, the test's commercial conduit, to either step up commercialization efforts or relinquish rights to the test back to Diag

Mar 17, 2014

DiagnoCure Q1 Revenues Fall 12 Percent on Weak Sales of Hologic-marketed Prostate Cancer Assay

NEW YORK (GenomeWeb News) – Cancer diagnostics firm DiagnoCure said on Friday that revenues for the first quarter of its fiscal year 2014 decreased 12 percent year over year.

Jun 03, 2013

DiagnoCure's Q2 Revenues Fall 85 Percent

NEW YORK (GenomeWeb News) – Canadian cancer diagnostics firm DiagnoCure reported after the close of the market on Monday that revenues for its fiscal second quarter fell 85 percent year over year.

Mar 11, 2013

DiagnoCure Q1 Revenues Slide 70 Percent

NEW YORK (GenomeWeb News) – Cancer diagnostic development company DiagnoCure reported after the close of the market Monday a 70 percent reduction in revenues in its fiscal first quarter.

Pages

The Scan

Plans Out

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

CovidNudge Numbers

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

Science Papers Propose Group to Discuss Genome-Editing Tools, Markers of Diabetes Drug Response, More

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

Not Counting These

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.